AtriCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AtriCure and other ETFs, options, and stocks.

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. 

CEO
Michael H. Carrel
CEOMichael H. Carrel
Employees
1,300
Employees1,300
Headquarters
Mason, Ohio
HeadquartersMason, Ohio
Founded
1994
Founded1994
Employees
1,300
Employees1,300

ATRC Key Statistics

Market cap
1.64B
Market cap1.64B
Price-Earnings ratio
-54.11
Price-Earnings ratio-54.11
Dividend yield
Dividend yield
Average volume
559.55K
Average volume559.55K
High today
$32.95
High today$32.95
Low today
$31.22
Low today$31.22
Open price
$31.44
Open price$31.44
Volume
465.03K
Volume465.03K
52 Week high
$43.11
52 Week high$43.11
52 Week low
$28.29
52 Week low$28.29

Stock Snapshot

The current AtriCure(ATRC) stock price is $32.90, with a market capitalization of 1.64B. The stock trades at a price-to-earnings (P/E) ratio of -54.11.

During the trading session on 2025-11-15, AtriCure(ATRC) shares reached a daily high of $32.95 and a low of $31.22. At a current price of $32.90, the stock is +5.4% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 465.03K, compared to an average daily volume of 559.55K.

The stock's 52-week range extends from a low of $28.29 to a high of $43.11.

The stock's 52-week range extends from a low of $28.29 to a high of $43.11.

ATRC News

Simply Wall St 5d
AtriCure Is Down 5.8% After Raising Revenue Guidance and Narrowing Net Loss – Has The Bull Case Changed?

AtriCure, Inc. recently reported third quarter 2025 results with sales rising to US$134.27 million and a significant reduction in net loss compared to the same...

AtriCure Is Down 5.8% After Raising Revenue Guidance and Narrowing Net Loss – Has The Bull Case Changed?

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ATRC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.